Company Insights

OABI customer relationships

Explore interactive graphBrowse insights index
OABI customer relationship map

OmniAb’s partner network: how licensing, royalties and services drive value for OABI investors

OmniAb builds and monetizes a proprietary platform that discovers fully human therapeutic antibodies and converts those discoveries into license agreements, fee-for-service programs, milestone payments and downstream royalties. Revenue flows are concentrated in partner deals with biopharma, academic centers and incubated ventures; the company’s financial upside is therefore a function of partner clinical progress and long‑tail royalty accruals rather than direct product sales. For investors evaluating OmniAb’s customer relationships, the roster of partners and the clinical advancement of partner assets are the primary value drivers. For a concise, relationship-first view of OmniAb’s commercial footprint visit https://nullexposure.com/.

How OmniAb actually captures economics

OmniAb’s operating model is transaction and partnership-driven: it licenses discovery technology and delivers discovery services to third parties, then collects a mix of upfront/license fees, R&D services revenue, milestone payments and royalties on partnered products. This structure produces high leverage to successful clinical readouts but results in revenue lumpiness and long realization timelines. Company-level signals from the public commentary and deal disclosures point to these characteristics:

  • Contracting posture: License-and-services orientation that prioritizes multiple deals across academic, biotech and pharma partners rather than internal late‑stage commercialization.
  • Concentration: Revenue is concentrated in partner milestones and royalties; a small number of successful partner programs can drive outsized upside.
  • Criticality: OmniAb’s platform is a foundational discovery engine for partners; royalties and milestone economics are therefore strategic to long‑term valuation.
  • Maturity: Many partner programs are in clinical or registration stages, introducing near- to medium-term catalysts while preserving substantial timing risk.

These are company-level signals derived from public deal disclosures and management commentary, not attribution to any single partner. For a deep dive into the partner list and source references, see the roster below and visit https://nullexposure.com/ for ongoing monitoring.

Who OmniAb is working with — the complete partner roster and what each relationship implies

Below are every customer relationship disclosed in OmniAb’s recent coverage, each with a concise, source-backed description.

  • Mabtrx Biosciences — OmniAb executed a technology license and services agreement with Mabtrx, an incubated company formed by ArrowMark Partners and Viking Global Investors; the deal was announced in a November 17, 2025 press release and reiterated on the Q4 2025 earnings call. This establishes OmniAb’s role as a discovery provider to newly formed investment vehicle incubators. (Press release, November 17, 2025; Q4 2025 earnings call transcript.)

  • Dana‑Farber Cancer Institute — OmniAb disclosed a new license agreement with Dana‑Farber during its Q4 2025 earnings call, reflecting ongoing academic collaborations that feed translational and potentially clinical programs. (Q4 2025 earnings call transcript.)

  • Merck KGaA — Merck KGaA intends to advance its OmniAb‑derived candidate M9140 directly to Phase III in metastatic colorectal cancer based on Phase I data, providing a clear near‑term clinical catalyst tied to OmniAb‑originated technology. (FY2026 partner update cited on the Q4 2025 call and transcript coverage.)

  • Arcus Biosciences — Arcus reported a 26.7‑month median overall survival from a Phase 2 gastric trial combining domvanalimab with OmniAb‑derived zimberelimab, underscoring the potential clinical impact of OmniAb discoveries in oncology. (FY2025 partner update described on the Q3 2025 earnings call transcript.)

  • Immunovant — Immunovant presented six‑month durability data at the American Thyroid Association meeting for batoclimab, a program leveraging OmniAb technology; management highlighted ongoing clinical momentum in the anti‑FcRn space. (FY2025 partner update on Q3 2025 call and reiterated in FY2026 commentary.)

  • Salubris Bio — Salubris’s anti‑PCSK9 candidate SAL003 moved from Phase III to the registration stage after NMPA acceptance of its NDA, illustrating a partner program that has reached regulatory filing status. (FY2025 partner update on Q3 2025 earnings call transcript.)

  • University of Leeds — OmniAb completed a license agreement with the University of Leeds during Q3 2025, signaling continued academic collaborations that broaden the platform’s scientific footprint. (Q3 2025 earnings call transcript.)

  • ASTAR — OmniAb completed a license agreement with ASTAR (Agency for Science, Technology and Research) in Q3 2025, reflecting strategic non‑commercial institutional partnerships in Asia. (Q3 2025 earnings call transcript.)

  • Teva — Teva announced funding support from Royalty Pharma to accelerate development of an OmniAb‑originated anti‑IL‑15 antibody (TEV‑408) for vitiligo; this financing arrangement underscores commercial commitment from a global pharma partner. (FY2026 partner update referenced on the Q4 2025 earnings call transcript.)

  • WuXi — A program that originated from an early partnership with WuXi carries a 3% global royalty to OmniAb, providing a concrete example of long‑term royalty income tied to partner commercialization. (FY2025 partner reference on Q3 2025 earnings call transcript.)

  • Hanall — Hanall is preparing an NDA submission in Japan for batoclimab as a treatment for myasthenia gravis, demonstrating regulatory progress for a partner program in an important regional market. (FY2026 partner update in Q4 2025 commentary.)

Each relationship above is drawn from OmniAb’s earnings call commentary and contemporaneous partner press coverage; together they represent OmniAb’s diversified partner mix across academia, biotech incubators and global pharma.

What this partnership map means for investors

OmniAb’s partner roster delivers a portfolio of potential revenue triggers with differing risk/reward profiles: clinical readouts (Merck KGaA, Arcus), regulatory filings (Salubris, Hanall), incubator licensing (Mabtrx) and steady royalty streams (WuXi). Key investment implications:

  • Catalyst-driven upside: Clinical advances by partners create the primary near-term valuation catalysts.
  • Revenue volatility: The licensing-and-services model produces lumpier top‑line growth, requiring investor patience for milestone realization.
  • Leverage to commercialization: Programs in Phase III and regulatory submission increase the probability of royalty accrual and milestone capture.
  • Diversification but dependency: The partner mix reduces single‑counterparty exposure but keeps company performance dependent on third‑party development decisions.

For investors and operators focused on partnership economics and royalty runway, OmniAb’s deal cadence and partner clinical updates are the single most important signals — track them closely at https://nullexposure.com/.

Bottom line and next steps for due diligence

OmniAb is a platform company that converts scientific discovery into license fees, services revenue and royalties, and the company’s near‑term valuation will be driven by partner clinical progress and registration events. Monitor the clinical milestones at Merck KGaA, Arcus, Salubris and the regulatory movements at Hanall and Teva for the clearest value inflection points. For ongoing monitoring of OmniAb’s partner activity and to receive updates tied to specific commercial milestones, visit https://nullexposure.com/.

If you want a tailored briefing on how these partner trajectories map into revenue scenarios and valuation sensitivity, the research resources at https://nullexposure.com/ provide structured, deal-level tracking and alerts.